Department of Internal Diseases and Cardiology, Centre for Management of Venous Thromboembolic Disease, Medical University of Warsaw, Warsaw, Poland.
Department of Internal Diseases and Cardiology, Centre for Management of Venous Thromboembolic Disease, Medical University of Warsaw, Warsaw, Poland
Pol Arch Intern Med. 2024 Apr 26;134(4). doi: 10.20452/pamw.16661. Epub 2024 Jan 11.
Acute pulmonary embolism (APE) is the most serious manifestation of venous thromboembolism. The simplified Pulmonary Embolism Severity Index (sPESI) is employed for prediction of 30-day mortality in APE. The Vulnerable Elders Survey (VES-13) is used to identify participants at a risk of health impairment.
We aimed to compare the VES-13 and sPESI scales for prediction of 3-month mortality inelderly patients hospitalized for APE.
All patients with APE were managed according to the European Society of Cardiology (ESC) guidelines and followed up for at least 3 months after discharge. Clinical evaluation of all patients involved the Charlson Comorbidity Index (CCI) and biochemical tests. The patients with VES-13 score equal to or above 3 (VES-13≥3) were evaluated with comprehensive geriatric assessment (CGA).
A total of 164 patients met the inclusion criteria. There were significantly fewer men in the VES-13≥3 than the VES-13<3 group (34% vs 54.5%; P <0.01). The patients in the VES-13≥3 group had lower median (interquartile range [IQR]) body mass index and higher sPESI score than those in the VES-13<3 group (25.6 [21.8-28.4] kg/m2 vs 28 [25.3-31] kg/m2; P = 0.001 and 2 [1-2] points vs 1 [0-1] point; P <0.001, respectively). There were no differences in APE severity according to the ESC stratification and CCI. Logistic regression analysis identified the VES-13 score as a significant independent risk factor for 3-month mortality.
The VES-13 score is a better tool than sPESI for predicting 3-month mortality. Geriatric survivors of APE characterized with VES-13≥3 points should be closely monitored after discharge. The Norton Scale Score in a combination with the VES-13 may be useful in predicting 3-month mortality among numerous tests used in the CGA.
急性肺栓塞(APE)是静脉血栓栓塞症最严重的表现。简化的肺栓塞严重程度指数(sPESI)用于预测 APE 患者 30 天死亡率。脆弱老年人调查(VES-13)用于识别有健康受损风险的参与者。
我们旨在比较 VES-13 和 sPESI 量表在预测因 APE 住院的老年患者 3 个月死亡率方面的作用。
所有 APE 患者均根据欧洲心脏病学会(ESC)指南进行治疗,并在出院后至少随访 3 个月。所有患者的临床评估均包括 Charlson 合并症指数(CCI)和生化检查。VES-13 评分等于或高于 3 分(VES-13≥3)的患者进行全面老年评估(CGA)。
共纳入 164 名符合条件的患者。VES-13≥3 组男性明显少于 VES-13<3 组(34% vs 54.5%;P<0.01)。VES-13≥3 组患者的中位数(四分位距 [IQR])体重指数和 sPESI 评分均低于 VES-13<3 组(25.6 [21.8-28.4]kg/m2 vs 28 [25.3-31]kg/m2;P=0.001 和 2 [1-2] 分 vs 1 [0-1] 分;P<0.001)。根据 ESC 分层和 CCI,APE 严重程度无差异。Logistic 回归分析确定 VES-13 评分是 3 个月死亡率的显著独立危险因素。
VES-13 评分是预测 3 个月死亡率的一个比 sPESI 更好的工具。具有 VES-13≥3 分的 APE 老年幸存者出院后应密切监测。Norton 量表评分与 VES-13 相结合可能有助于预测 CGA 中众多检测方法预测的 3 个月死亡率。